[go: up one dir, main page]

AR130477A1 - C5AR1 ANTAGONISTS AND THEIR USES - Google Patents

C5AR1 ANTAGONISTS AND THEIR USES

Info

Publication number
AR130477A1
AR130477A1 ARP230102436A ARP230102436A AR130477A1 AR 130477 A1 AR130477 A1 AR 130477A1 AR P230102436 A ARP230102436 A AR P230102436A AR P230102436 A ARP230102436 A AR P230102436A AR 130477 A1 AR130477 A1 AR 130477A1
Authority
AR
Argentina
Prior art keywords
c5ar1
compounds
antagonists
receptor
antagonize
Prior art date
Application number
ARP230102436A
Other languages
Spanish (es)
Inventor
Kevin Hunt
Jianbin Zheng
sida Shen
Original Assignee
Vanqua Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanqua Bio Inc filed Critical Vanqua Bio Inc
Publication of AR130477A1 publication Critical patent/AR130477A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente memoria se proporcionan compuestos que modulan (por ejemplo, antagonizan) el receptor para el componente 5a del complemento 1 (C5aR1), un receptor acoplado a la proteína G para C5a que se asocia con trastornos autoinmunitarios, inflamatorios y neurodegenerativos. Además, se proporcionan composiciones farmacéuticas y kits que comprenden los compuestos y los métodos para tratar enfermedades y trastornos relacionados con el C5aR1 con los compuestos en un sujeto, mediante la administración de los compuestos y/o las composiciones que se describen en la presente memoria. Un compuesto con la fórmula (1).Provided herein are compounds that modulate (e.g., antagonize) the complement component 5a receptor 1 (C5aR1), a G protein-coupled receptor for C5a that is associated with autoimmune, inflammatory, and neurodegenerative disorders. Furthermore, provided are pharmaceutical compositions and kits comprising the compounds and methods for treating diseases and disorders related to C5aR1 with the compounds in a subject, by administering the compounds and/or compositions described herein. A compound of formula (1).

ARP230102436A 2022-09-14 2023-09-13 C5AR1 ANTAGONISTS AND THEIR USES AR130477A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263406501P 2022-09-14 2022-09-14

Publications (1)

Publication Number Publication Date
AR130477A1 true AR130477A1 (en) 2024-12-11

Family

ID=90275968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102436A AR130477A1 (en) 2022-09-14 2023-09-13 C5AR1 ANTAGONISTS AND THEIR USES

Country Status (4)

Country Link
EP (1) EP4587014A2 (en)
AR (1) AR130477A1 (en)
TW (1) TW202425978A (en)
WO (1) WO2024059096A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025176748A1 (en) * 2024-02-22 2025-08-28 F. Hoffmann-La Roche Ag Condensed pyrazines or pyrimidines als trem2 agoonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100828982B1 (en) * 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 Pyridone derivative having affinity for cannabinoid 2-type receptor
WO2017014201A1 (en) * 2015-07-17 2017-01-26 富士フイルム株式会社 Nitrogen-containing heterocyclic compound
KR102476818B1 (en) * 2019-05-31 2022-12-13 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

Also Published As

Publication number Publication date
WO2024059096A3 (en) 2024-04-25
TW202425978A (en) 2024-07-01
EP4587014A2 (en) 2025-07-23
WO2024059096A2 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
UY40204A (en) Complement Factor B Inhibitors and Their Uses
ECSP21004787A (en) INFLAMASOME INHIBITORS NLRP3
ECSP21027049A (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS
MX2021014728A (en) THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS.
UY39527A (en) COMPOSITIONS OF INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS
UY39857A (en) LIPIDATED PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
ECSP23044370A (en) PHARMACEUTICAL COMPOUNDS
CO2019007409A2 (en) Tricyclic enone pyrimidin derivatives for rorγ inhibition and other uses
ES3052569T3 (en) Oxadiazole compounds as transient receptor potential channel inhibitors
CL2017002799A1 (en) Tricyclic sulfones as modulators of the orphan receptor related to gamma retinoid (rory)
AR123685A1 (en) MRGX2 ANTAGONISTS
CL2022001741A1 (en) Cyclic compounds and methods of using same
MX2020011405A (en) BENCIMIDAZOLE DERIVATIVES AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORY) MODULATORS AND PHARMACEUTICAL USES THEREOF.
MX2020004810A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases.
AR127470A1 (en) LRRK2 INHIBITORS
CO2021014223A2 (en) New compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR133953A1 (en) COMPLEMENT FACTOR B INHIBITORS AND THEIR USES
ECSP19072975A (en) PYRAZOLE [1,5-A] PYRIMIDINE DERIVATIVES REPLACED WITH PHARMACOLOGICALLY ACTIVE ALLICYCLICS
AR130477A1 (en) C5AR1 ANTAGONISTS AND THEIR USES
CO2018007436A2 (en) Alkyl dihydroquinolinsulfonamide compounds
UY39681A (en) 1,3-Substituted Cyclobutyl Derivatives and Their Uses
CO2024003953A2 (en) Benzodiazepine derivatives as positive allosteric modulators of the gaba to gamma1 receptor
ECSP22003596A (en) NMDA RECEPTOR MODULATORS
UY37745A (en) BICYCLIC COMPOUNDS 5.6 FUSIONATES AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
AR133582A1 (en) BICYCLIC HETEROCYCLES AS ANTAGONISTS OF MRGPRX2